Status of minimal residual disease testing in childhood haematological malignancies
about
Current Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic LeukemiaHow I treat pediatric acute myeloid leukemiaChildhood acute myeloid leukaemiaviSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia.Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia.Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia.High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia.Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia.Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia.Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.Progress of minimal residual disease studies in childhood acute leukemia.Minimal residual disease in acute lymphoblastic leukemiaAcute lymphoblastic leukemia: introduction.Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia.HLA-DPβ1 Asp84-Lys69 antigen-binding signature predicts event-free survival in childhood B-cell precursor acute lymphoblastic leukaemia: results from the MRC UKALL XI childhood ALL trial.The effect of body mass index at diagnosis on clinical outcome in children with newly diagnosed acute lymphoblastic leukemia.
P2860
Q26751269-196DD5E3-6CCC-4262-B34F-0ACD803992A0Q26992280-C21E748C-E912-4396-93D1-2E5DD347C669Q27005960-5A75768B-8C6F-4084-AEB5-9EEEF42512B7Q30628090-72C9C93C-9EFD-489A-ADD0-349E66CE6832Q33886177-7FA2F22C-76CA-481A-936C-542B43359684Q33931882-9F5B6EB7-57E5-40BB-94A9-8CE9C98F8554Q35112199-01AC2D4B-945D-4E97-8A29-5F515DC577EDQ35791247-ECF331D4-4586-4ADC-8FC1-5D40B8C76E21Q36100435-C6355352-A3C1-4005-9B19-1505727A9124Q36194222-59D0A3F0-35FF-4DE1-8591-D931210D993EQ36981845-40B5DEA1-D0D4-4930-800E-64846A5CE686Q37077352-6208663F-2440-4267-86CC-AA1835DF30ECQ37090268-D2FCA76E-E234-4BBC-9CEF-79525C784675Q37389632-207797F9-68FF-4B47-9325-778D0EB187CDQ41813372-692A2FB2-F181-46A4-8227-2F764AA66955Q42339287-08CD4BD5-1C06-4242-9336-CB25E769F266
P2860
Status of minimal residual disease testing in childhood haematological malignancies
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Status of minimal residual disease testing in childhood haematological malignancies
@en
Status of minimal residual disease testing in childhood haematological malignancies.
@nl
type
label
Status of minimal residual disease testing in childhood haematological malignancies
@en
Status of minimal residual disease testing in childhood haematological malignancies.
@nl
prefLabel
Status of minimal residual disease testing in childhood haematological malignancies
@en
Status of minimal residual disease testing in childhood haematological malignancies.
@nl
P2860
P1476
Status of minimal residual disease testing in childhood haematological malignancies
@en
P2093
Dario Campana
P2860
P304
P356
10.1111/J.1365-2141.2008.07350.X
P407
P577
2008-08-15T00:00:00Z